Biomarin Pharmaceutical Inc. (BMRN) upgraded to Buy with price target $41 by Brean Murray
Brean Murray rated Buy Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) on 03/19/2012, when the stock price was $35.56. Since
then, Biomarin Pharmaceutical Inc. has gained 96.85% as of 12/09/2013's recent price of $70.00. If you would have followed this Brean Murray's recommendation on BMRN, you would have gained 96.85% of your investment in 630 days.
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.
Our equity research department is focused on fundamental analysis across the universe of over 200 small/mid cap stocks in our five target sectors. We are committed to providing proprietary action-oriented research to our institutional clients.
Small cap growth focus. Our primary area of concentration is growth stocks with market capitalization of $200 million to $5 billion.
Global perspective. We are covering U.S. listed stocks for companies domiciled in the U.S., China, Europe and Latin America, with our biggest concentration in the US and China. We were one of the first banks to aggressively expand our research to China and we believe we created one of the premier research franchises in small cap, U.S. listed Chinese companies to complement our strong domestic coverage.
Disciplined stock selection. Our research analysts are focused on performing extensive bottoms up due diligence on companies under our coverage by leveraging their industry and management contacts. By combining our bottoms up work with our sector views we seek to generate a consistent flow of high conviction ideas for our clients.
Diversified coverage. Our areas of expertise include technology, consumer, healthcare, resources and China small cap. We provide our clients with company-specific as well as sector-specific research across our target sectors.